Acute Lymphocytic Leukemia Therapeutics Market: Industry Analysis and Forecast (2021-2027) by Therapy, Type, and Region

Acute Lymphocytic Leukemia Therapeutics Market size was valued at US$ 3.24 Bn. in 2020 and the total revenue is expected to grow at 4.3% through 2021 to 2027, reaching nearly US$ 4.35 Bn.

Acute Lymphocytic Leukemia Therapeutics Market Overview:

Acute lymphocytic leukemia (ALL) is a blood and bone marrow malignancy that affects the spongy tissue inside bones that produces blood cells. The term "acute" stems from the fact that acute lymphocytic leukemia advances quickly and produces immature blood cells rather than mature ones. In acute lymphocytic leukemia, the term "lymphocytic" refers to the white blood cells known as lymphocytes, which are affected by ALL. The most frequent type of cancer in children is acute lymphocytic leukemia, which has a fair chance of being cured. Adults can also develop acute lymphocytic leukemia, albeit the chances of a cure are slim. Acute Lymphocytic Leukemia Therapeutics Market To know about the Research Methodology :- Request Free Sample Report The report has covered the market trends from 2015 to forecast the market through 2027. 2020 is considered a base year however 2020's numbers are on the real output of the companies in the market. Special attention is given to 2020 and the effect of lockdown on the demand and supply, and also the impact of lockdown for the next two years on the market. Some companies have done good in lockdown also and specific strategic analysis of those companies is done in the report

Acute Lymphocytic Leukemia Therapeutics Market Dynamics:

A rise in the incidence of Acute Lymphoblastic Leukemia (ALL) and an increase in public and private sector activities are two significant drivers projected to propel market expansion. One of the market's development factors is technological advancements that allow for the detection of damaged cells. Novartis AG's Chimeric Antigen Receptor (CAR)-T cell therapy, for example, is a revolutionary treatment. On August 30, 2017, the USFDA approved Kymriah Tm (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, the first chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL) patients aged 25 and up who are refractory or in second or later relapse. Kymriah is a revolutionary immune cellular therapy that employs a patient's T cells to attack cancer. It is a one-time treatment. The FDA has approved Kymriah, the first gene-transfer therapy. Hence, rising regulatory approvals are likely to motivate the growth of the market in the forecast period. The American Cancer Society, the National Cancer Institute (NCI), and the Foundation for the National Institutes of Health have all launched projects and organized diagnostic campaigns to detect ALL. Furthermore, the "Therapeutically Applicable Research to Generate Effective Treatments (TARGET)" intervention and the "Childhood Cancer Targeted Therapeutics Workshop" has launched a number of programs and collaborated with several research groups from around the world, including St. Jude Children's Research Hospital and the University of New Mexico, to provide patients with early diagnosis and better leukemia treatment.

Acute Lymphocytic Leukemia Therapeutics Market Segment Analysis:

The Chemotherapy segment is dominating the Therapy segment of the Acute Lymphocytic Leukemia Therapeutics Market:

Chemotherapy dominated the market in 2016 because of its capacity to eradicate leukemia cells and prevent malignant cells from growing and multiplying, hence slowing disease progression. All of these variables have contributed to the rise in chemotherapy prescription rates during the last two decades. Single or combination medications (chemotherapy regimen) are used to treat ALL in chemotherapy. Cytotoxic agents, antimetabolites, alkylating compounds, and other plant derivatives are all used in this therapy. Additionally, stem cell implantation can be paired with chemotherapy, allowing doctors to use high-dose chemotherapy infusions to treat patients effectively. Over the predicted period, targeted therapy will be the fastest expanding segment. In comparison to chemotherapy, this therapy provides advantages such as greater therapeutic precision and efficiency, as well as speedier recovery. Furthermore, the market is being driven by an increased desire for tailored medicines for the treatment of this ailment. The Philadelphia (Ph) Chromosome segment is considered to supplement the growth of the Acute Lymphocytic Leukemia Therapeutics Market. During the projection period, Philadelphia (Ph) Chromosomes is expected to contribute to the market's growth. ALL with a Ph-positive phenotype and ALL with a Ph-negative phenotype The Philadelphia (Ph) chromosome has two subgroups. As people age, their chances of acquiring this disease increase. ALL is often treated with tyrosine kinase inhibitors such as dasatinib (Sprycel), imatinib (Glivec), and nilotinib (Tasigna). One of the indications for the drug mentioned above is acute lymphoblastic leukemia. A drug used to treat chronic myeloid leukemia can usually be utilized to treat acute lymphoblastic leukemia as well. Acute Lymphocytic Leukemia Therapeutics Market

Acute Lymphocytic Leukemia Therapeutics Market Regional Insights:

North America is estimated to dominate the growth of the Acute Lymphocytic Leukemia Therapeutics Market. In 2019, North America dominated the market. The presence of important manufacturers in the United States, as well as a well-established healthcare infrastructure and technological advancement, are the main reasons that contribute to its large market share. Furthermore, due to the debut of the medicine response (inotuzumab ozogamicin) in August 2017 and the presence of strong pipeline drugs such as eryaspase (asparaginase), which is in phase II clinical trials, the United States is expected to see significant growth. Further, growing private healthcare organizations and high purchasing power individuals are likely to motivate the growth of the market in the forecast period.   The objective of the report is to present a comprehensive analysis of the Acute Lymphocytic Leukemia Therapeutics Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding the Acute Lymphocytic Leukemia Therapeutics Market dynamics, structure by analyzing the market segments and projecting the Acute Lymphocytic Leukemia Therapeutics Market size. Clear representation of competitive analysis of key players by Grade, price, financial position, Grade portfolio, growth strategies, and regional presence in the Acute Lymphocytic Leukemia Therapeutics Market make the report investor’s guide.

Acute Lymphocytic Leukemia Therapeutics Market Scope: Inquire before buying

Acute Lymphocytic Leukemia Therapeutics Market

Acute Lymphocytic Leukemia Therapeutics Market, by Region

• North America o US o Canada o Mexico • Europe o U.K o France o Germany o Italy o Spain o Sweden o CIS Countries o Rest of Europe • Asia Pacific o China o India o Japan o South Korea o Australia o ASEAN o Rest of Asia Pacific • The Middle East and Africa o South Africa o GCC Countries o Egypt o Nigeria o Rest of ME&A • South America o Brazil o Argentina o Rest of South America

Acute Lymphocytic Leukemia Therapeutics Market Key Player

Erytech PharmaSpectrum Pharmaceuticals, Inc.Pfizer, Inc. • Sigma-Tau s.p.a. • Genzyme Corporation • Amgen, Inc. • Bristol-Myers Squibb Company • Erytech Pharma • Leadiant Biosciences, Inc. (Sigma-Tau Pharmaceuticals Inc.) • Novartis AG • Pfizer, Inc. • Rare Disease Therapeutics, Inc. • Sanofi • Spectrum Pharmaceuticals, Inc • Takeda Pharmaceutical Company Limited.

FAQs:

1. What is the Acute Lymphocytic Leukemia Therapeutics market value in 2020? Ans: Acute Lymphocytic Leukemia Therapeutics market value in 2020 was estimated as 3.24 Billion USD. 2. What is the Acute Lymphocytic Leukemia Therapeutics market growth? Ans: The Acute Lymphocytic Leukemia Therapeutics market is anticipated to grow with a CAGR of 4.3% in the forecast period and is likely to reach USD 4.35 Billion by the end of 2027. 3. Which segment is expected to dominate the Acute Lymphocytic Leukemia Therapeutics market during the forecast period? Ans: North America dominated the market. The presence of important manufacturers in the United States, as well as a well-established healthcare infrastructure and technological advancement, are main reasons that contribute to its large market share 4. Who are the key players in the Acute Lymphocytic Leukemia Therapeutics market? Ans: Some of the key players are Erytech Pharma; Spectrum Pharmaceuticals, Inc.; Pfizer, Inc.; Sigma-Tau s.p.a.; and Genzyme Corporation. 5. What is the key driving factor for the growth of the Acute Lymphocytic Leukemia Therapeutics market? Ans: Rise in incidence of Acute Lymphoblastic Leukemia (ALL) and increase in initiatives undertaken by public and private organizations are some of the key factors expected to drive market growth.
1. Preface 1.1. Market Definition and Key Research Objectives 1.2. Research Highlights 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Acute Lymphocytic Leukemia Therapeutics Market Size, by Market Value (US$ Bn) 3.1. Global Market Segmentation 3.2. Global Market Segmentation Share Analysis, 2020 3.2.1. Global 3.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 3.3. Geographical Snapshot of the Acute Lymphocytic Leukemia Therapeutics Market 3.4. Geographical Snapshot of the Acute Lymphocytic Leukemia Therapeutics Market, By Manufacturer share 4. Acute Lymphocytic Leukemia Therapeutics Market Overview, 2020-2027 4.1. Market Dynamics 4.1.1. Drivers 4.1.1.1. Global 4.1.1.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.2. Restraints 4.1.2.1. Global 4.1.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.3. Opportunities 4.1.3.1. Global 4.1.3.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.4. Challenges 4.1.4.1. Global 4.1.4.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.5. Industry Trends and Emerging Technologies 4.1.6. Porter Five Forces Analysis 4.1.6.1. The threat of New Entrants 4.1.6.2. Bargaining Power of Buyers/Consumers 4.1.6.3. Bargaining Power of Suppliers 4.1.6.4. The threat of Substitute Grades 4.1.6.5. The intensity of Competitive Rivalry 4.1.7. Value Chain Analysis 4.1.8. Technological Roadmap 4.1.9. Regulatory landscape 4.1.10. Impact of the Covid-19 Pandemic on the Acute Lymphocytic Leukemia Therapeutics Market 5. Supply Side and Demand Side Indicators 6. Acute Lymphocytic Leukemia Therapeutics Market Analysis and Forecast, 2020-2027 6.1. Acute Lymphocytic Leukemia Therapeutics Market Size & Y-o-Y Growth Analysis. 7. Acute Lymphocytic Leukemia Therapeutics Market Analysis and Forecasts, 2020-2027 7.1. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 7.1.1. Chemotherapy 7.1.1.1. Hyper-CVAD 7.1.1.2. CALGB 8811 regimen 7.1.1.3. Linker regimen 7.1.1.4. Nucleoside Metabolic Inhibitors 7.1.1.5. Oncaspar 7.1.2. Targeted therapy 7.1.3. Radiation Therapy 7.1.4. Stem cell transplantation 7.2. Market Size (Value) Estimates & Forecast By Type, 2020-2027 7.2.1. Philadelphia chromosome 7.2.2. Precursor B-cell ALL 7.2.3. T-cell ALL 8. Acute Lymphocytic Leukemia Therapeutics Market Analysis and Forecasts, By Region 8.1. Market Size (Value) Estimates & Forecast By Region, 2020-2027 8.1.1. North America 8.1.2. Europe 8.1.3. Asia-Pacific 8.1.4. Middle East & Africa 8.1.5. South America 9. North America Acute Lymphocytic Leukemia Therapeutics Market Analysis and Forecasts, 2020-2027 9.1. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 9.1.1. Chemotherapy 9.1.1.1. Hyper-CVAD 9.1.1.2. CALGB 8811 regimen 9.1.1.3. Linker regimen 9.1.1.4. Nucleoside Metabolic Inhibitors 9.1.1.5. Oncaspar 9.1.2. Targeted therapy 9.1.3. Radiation Therapy 9.1.4. Stem cell transplantation 9.2. Market Size (Value) Estimates & Forecast By Type, 2020-2027 9.2.1. Philadelphia chromosome 9.2.2. Precursor B-cell ALL 9.2.3. T-cell ALL 10. North America Acute Lymphocytic Leukemia Therapeutics Market Analysis and Forecasts, By Country 10.1. Market Size (Value) Estimates & Forecast By Country, 2020-2027 10.1.1. US 10.1.2. Canada 10.1.3. Mexico 11. U.S. Acute Lymphocytic Leukemia Therapeutics Market Analysis and Forecasts, 2020-2027 11.1. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 11.2. Market Size (Value) Estimates & Forecast By Type, 2020-2027 12. Canada Acute Lymphocytic Leukemia Therapeutics Market Analysis and Forecasts, 2020-2027 12.1. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 12.2. Market Size (Value) Estimates & Forecast By Type, 2020-2027 13. Mexico Acute Lymphocytic Leukemia Therapeutics Market Analysis and Forecasts, 2020-2027 13.1. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 13.2. Market Size (Value) Estimates & Forecast By Type, 2020-2027 14. Europe Acute Lymphocytic Leukemia Therapeutics Market Analysis and Forecasts, 2020-2027 14.1. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 14.2. Market Size (Value) Estimates & Forecast By Type, 2020-2027 15. Europe Acute Lymphocytic Leukemia Therapeutics Market Analysis and Forecasts, By Country 15.1. Market Size (Value) Estimates & Forecast By Country, 2020-2027 15.1.1. U.K 15.1.2. France 15.1.3. Germany 15.1.4. Italy 15.1.5. Spain 15.1.6. Sweden 15.1.7. CIS Countries 15.1.8. Rest of Europe 16. U.K Acute Lymphocytic Leukemia Therapeutics Market Analysis and Forecasts, 2020-2027 16.1. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 16.2. Market Size (Value) Estimates & Forecast By Type, 2020-2027 17. France Acute Lymphocytic Leukemia Therapeutics Market Analysis and Forecasts, 2020-2027 17.1. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 17.2. Market Size (Value) Estimates & Forecast By Type, 2020-2027 18. Germany Acute Lymphocytic Leukemia Therapeutics Market Analysis and Forecasts, 2020-2027 18.1. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 18.2. Market Size (Value) Estimates & Forecast By Type, 2020-2027 19. Italy Acute Lymphocytic Leukemia Therapeutics Market Analysis and Forecasts, 2020-2027 19.1. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 19.2. Market Size (Value) Estimates & Forecast By Type, 2020-2027 20. Spain Acute Lymphocytic Leukemia Therapeutics Market Analysis and Forecasts, 2020-2027 20.1. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 20.2. Market Size (Value) Estimates & Forecast By Type, 2020-2027 21. Sweden Acute Lymphocytic Leukemia Therapeutics Market Analysis and Forecasts, 2020-2027 21.1. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 21.2. Market Size (Value) Estimates & Forecast By Type, 2020-2027 22. CIS Countries Acute Lymphocytic Leukemia Therapeutics Market Analysis and Forecasts, 2020-2027 22.1. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 22.2. Market Size (Value) Estimates & Forecast By Type, 2020-2027 23. Rest of Europe Acute Lymphocytic Leukemia Therapeutics Market Analysis and Forecasts, 2020-2027 23.1. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 23.2. Market Size (Value) Estimates & Forecast By Type, 2020-2027 24. Asia Pacific Acute Lymphocytic Leukemia Therapeutics Market Analysis and Forecasts, 2020-2027 24.1. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 24.2. Market Size (Value) Estimates & Forecast By Type, 2020-2027 25. Asia Pacific Acute Lymphocytic Leukemia Therapeutics Market Analysis and Forecasts, by Country 25.1. Market Size (Value) Estimates & Forecast By Country, 2020-2027 25.1.1. China 25.1.2. India 25.1.3. Japan 25.1.4. South Korea 25.1.5. Australia 25.1.6. ASEAN 25.1.7. Rest of Asia Pacific 26. China Acute Lymphocytic Leukemia Therapeutics Market Analysis and Forecasts, 2020-2027 26.1. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 26.2. Market Size (Value) Estimates & Forecast By Type, 2020-2027 27. India Acute Lymphocytic Leukemia Therapeutics Market Analysis and Forecasts, 2020-2027 27.1. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 27.2. Market Size (Value) Estimates & Forecast By Type, 2020-2027 28. Japan Acute Lymphocytic Leukemia Therapeutics Market Analysis and Forecasts, 2020-2027 28.1. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 28.2. Market Size (Value) Estimates & Forecast By Type, 2020-2027 29. South Korea Acute Lymphocytic Leukemia Therapeutics Market Analysis and Forecasts, 2020-2027 29.1. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 29.2. Market Size (Value) Estimates & Forecast By Type, 2020-2027 30. Australia Acute Lymphocytic Leukemia Therapeutics Market Analysis and Forecasts, 2020-2027 30.1. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 30.2. Market Size (Value) Estimates & Forecast By Type, 2020-2027 31. ASEAN Acute Lymphocytic Leukemia Therapeutics Market Analysis and Forecasts, 2020-2027 31.1. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 31.2. Market Size (Value) Estimates & Forecast By Type, 2020-2027 32. Rest of Asia Pacific Acute Lymphocytic Leukemia Therapeutics Market Analysis and Forecasts, 2020-2027 32.1. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 32.2. Market Size (Value) Estimates & Forecast By Type, 2020-2027 33. Middle East Africa Acute Lymphocytic Leukemia Therapeutics Market Analysis and Forecasts, 2020-2027 33.1. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 33.2. Market Size (Value) Estimates & Forecast By Type, 2020-2027 34. Middle East Africa Acute Lymphocytic Leukemia Therapeutics Market Analysis and Forecasts, by Country 34.1. Market Size (Value) Estimates & Forecast by Country, 2020-2027 34.1.1. South Africa 34.1.2. GCC Countries 34.1.3. Egypt 34.1.4. Nigeria 34.1.5. Rest of ME&A 35. South Africa Acute Lymphocytic Leukemia Therapeutics Market Analysis and Forecasts, 2020-2027 35.1. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 35.2. Market Size (Value) Estimates & Forecast By Type, 2020-2027 36. GCC Countries Acute Lymphocytic Leukemia Therapeutics Market Analysis and Forecasts, 2020-2027 36.1. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 36.2. Market Size (Value) Estimates & Forecast By Type, 2020-2027 37. Egypt Textile Reinforced Concrete e-Market Analysis and Forecasts, 2020-2027 37.1. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 37.2. Market Size (Value) Estimates & Forecast By Type, 2020-2027 38. Nigeria Acute Lymphocytic Leukemia Therapeutics Market Analysis and Forecasts, 2020-2027 38.1. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 38.2. Market Size (Value) Estimates & Forecast By Type, 2020-2027 39. Rest of ME&A Acute Lymphocytic Leukemia Therapeutics Market Analysis and Forecasts, 2020-2027 39.1. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 39.2. Market Size (Value) Estimates & Forecast By Type, 2020-2027 40. South America Acute Lymphocytic Leukemia Therapeutics Market Analysis and Forecasts, 2020-2027 40.1. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 40.2. Market Size (Value) Estimates & Forecast By Type, 2020-2027 41. South America Acute Lymphocytic Leukemia Therapeutics Market Analysis and Forecasts, by Country 41.1. Market Size (Value) Estimates & Forecast by Country, 2020-2027 41.1.1. Brazil 41.1.2. Argentina 41.1.3. Rest of South America 42. Brazil Acute Lymphocytic Leukemia Therapeutics Market Analysis and Forecasts, 2020-2027 42.1. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 42.2. Market Size (Value) Estimates & Forecast By Type, 2020-2027 43. Argentina Acute Lymphocytic Leukemia Therapeutics Market Analysis and Forecasts, 2020-2027 43.1. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 43.2. Market Size (Value) Estimates & Forecast By Type, 2020-2027 44. Rest of South America Acute Lymphocytic Leukemia Therapeutics Market Analysis and Forecasts, 2020-2027 44.1. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 44.2. Market Size (Value) Estimates & Forecast By Type, 2020-2027 45. Competitive Landscape 45.1. Geographic Footprint of Major Players in the Acute Lymphocytic Leukemia Therapeutics Market 45.2. Competition Matrix 45.2.1. Competitive Benchmarking of Key Players By Price, Presence, Market Share, Fiber Grades, and R&D Investment 45.2.2. New Grade Launches and Grade Enhancements 45.2.3. Market Consolidation 45.2.3.1. M&A by Regions, Investment, and Verticals 45.2.3.2. M&A, Forward Integration and Backward Integration 45.2.3.3. Partnership, Joint Ventures, and Strategic Alliances/ Sales Agreements 45.3. Company Profile: Key Players 45.3.1. Novartis AG 45.3.1.1. Company Overview 45.3.1.2. Financial Overview 45.3.1.3. Geographic Footprint 45.3.1.4. Grade Portfolio 45.3.1.5. Business Strategy 45.3.1.6. Recent Development 45.3.2. Esaote S.p.A 45.3.3. Mindray Bio-Medical Electronics Co. Ltd. 45.3.4. Analogic Corporation 45.3.5. General Electric Company 45.3.6. Siemens AG 45.3.7. Fujifilm Holdings Corporation 45.3.8. Samsung Electronics Co. Ltd. 45.3.9. Koninklijke Philips N.V. 45.3.10. Canon Medical Systems Corporation. 45.3.11. Butterfly Network Inc. 45.3.12. Teknova Medical System 45.3.13. Advanced Instrumentation 45.3.14. DRE medical 45.3.15. Landwind Medical 45.3.16. EDAN instrument 45.3.17. Terason Corporation 45.3.18. GE healthcare 45.3.19. FujiFilm Sonosite 45.3.20. Hitachi Ltd 46. Primary Key Insights

About This Report

Report ID 125007
Category Healthcare
Published Date Oct 2021
Updated Date
Contact Us